Loading…
Cartesian Therapeutics, Inc. is projected to rise to $8.19 by 2027, a +5% move from its current price of $7.80. RNAC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $7.52 | $7.80 | $8.09 | +0.01% |
| Aug 4 | $7.41 | $7.80 | $8.21 | +0.02% |
| Aug 5 | $7.33 | $7.80 | $8.31 | +0.03% |
| Aug 6 | $7.25 | $7.80 | $8.39 | +0.04% |
| Aug 7 | $7.19 | $7.80 | $8.47 | +0.05% |
| Aug 8 | $7.14 | $7.80 | $8.53 | +0.06% |
| Aug 9 | $7.09 | $7.81 | $8.59 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.09 | $7.81 | $8.59 | +0.07% |
| Week 2 | $6.82 | $7.81 | $8.95 | +0.13% |
| Week 3 | $6.61 | $7.82 | $9.23 | +0.20% |
| Week 4 | $6.45 | $7.82 | $9.48 | +0.26% |
| Week 5 | $6.31 | $7.83 | $9.71 | +0.33% |
| Week 6 | $6.18 | $7.83 | $9.92 | +0.40% |
| Week 7 | $6.07 | $7.84 | $10.11 | +0.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. Its lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against BCMA, in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, with a rare pediatric disease designation for juvenile dermatomyositis.
The company is headquartered in Frederick, Maryland and operates in the Healthcare sector.
The company is also developing Descartes-15, which is in phase 1 trials and is an autologous BCMA-directed mRNA CAR-T to treat patients with multiple myeloma. These programs position Cartesian Therapeutics as a clinical-stage biotech focused on mRNA CAR-T therapies for autoimmune and hematologic diseases.
RNAC is the stock for Cartesian Therapeutics, Inc. It is currently priced at $7.92 and has a market capitalization of $232.7M, with a rank of 3617. The near-term price outlook reflects a neutral stance amid a trading range that sits around the current price.
The forecast trajectory shows a path from the current level toward higher prices in the longer term, with notable upside in the 2030s and beyond.
Key forecast points include a 2026 average price of $7.92, rising toward $10.59 by 2030, then extending to $25.81 by 2040 and $38.10 by 2050, with corresponding increases in modeled return potential. These figures imply a stepwise improvement in valuation and a shift toward bullish momentum in the later years of the forecast.
A major floor 30.3% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 35.8% above — a clean break opens room to run.
A major ceiling 50.9% above — clearing it would confirm fresh momentum.
Key RNAC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNAC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.68 | Buy | $7.75 | Buy |
| MA 10 | $7.86 | Sell | $7.93 | Sell |
| MA 20 | $8.55 | Sell | $8.27 | Sell |
| MA 50 | $8.30 | Sell | $8.27 | Sell |
| MA 100 | $7.60 | Buy | $8.01 | Sell |
| MA 200 | $7.57 | Buy | $8.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.36 | Neutral |
| Stoch RSI (14) | 56.57 | Neutral |
| CCI (20) | -67.83 | Neutral |
| Williams %R (14) | -69.84 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -10.14 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 30.16 | Neutral |
| TRIX (15) | -0.31 | Sell |
| Awesome (5,34) | -1.34 | Sell |
| Ultimate (7,14,28) | 32.42 | Neutral |
| Momentum (10) | -0.46 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 7.55 | Buy |
| ADX (14) | 18.91 | Neutral |
| ATR (14) | 0.25 | Info |
The near-term technical picture is neutral, with an RSI of 40. The 14-day RSI sits in the lower half of the range, indicating modest momentum. The 50-day simple moving average (SMA50) sits at $8.29, while the 200-day simple moving average (SMA200) is at $7.63, placing the price near key trend indicators.
Near-term support is listed at $7.43 and resistance at $10.59, framing a defined range. The 30-day price range spans from $6.01 to $10.44, highlighting trading activity within that window and suggesting potential for movement within the established levels before a longer-term directional shift.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.84 | $7.80 | $10.30 | 0% | Neutral | |
| $6.33 | $8.19 | $11.31 | +5% | Neutral | |
| $6.10 | $8.21 | $11.89 | +5% | Neutral | |
| $6.99 | $9.71 | $14.59 | +24% | Bullish | |
| $7.77 | $11.12 | $17.23 | +43% | Bullish | |
| $8.86 | $13.01 | $20.71 | +67% | Bullish | |
| $10.31 | $15.52 | $25.29 | +99% | Bullish | |
| $9.97 | $15.37 | $25.59 | +97% | Bullish | |
| $10.02 | $15.80 | $26.83 | +103% | Bullish | |
| $10.29 | $16.58 | $28.67 | +113% | Bullish | |
| $15.27 | $27.19 | $50.70 | +249% | Bullish | |
| $20.41 | $43.54 | $90.44 | +458% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.84 | $7.80 | $9.84 | +0.00% |
| September 2026 | $6.71 | $8.02 | $9.90 | +2.79% |
| October 2026 | $6.53 | $7.87 | $9.85 | -1.88% |
| November 2026 | $6.64 | $8.07 | $10.22 | +2.53% |
| December 2026 | $6.58 | $8.05 | $10.30 | -0.18% |
Click any year to see its month-by-month RNAC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RNAC to range from $5.84 to $10.30 through 2026. The $7.80 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RNAC price prediction for 2027 points to an average of $8.19 (low $6.33, high $11.31) — a potential gain of +5% on today's $7.80. Price action looks broadly range-bound.
In 2028, RNAC is projected to trade between $6.10 and $11.89, averaging $8.21 — a potential gain of +5% from today's $7.80. That is up 0% on the projected 2027 average. A consolidation phase looks the most probable path here.
Cartesian Therapeutics, Inc.'s 2029 outlook centres on $9.71, within a $6.99 to $14.59 range. That is up +18% on the projected 2028 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2030, RNAC could reach as high as $17.23, with a base case around $11.12 and support toward $7.77 — roughly +43% from $7.80. Buyers look set to stay in control over this stretch.
Expect RNAC to range from $8.86 to $20.71 through 2031. The $13.01 average target implies a +67% move from current prices. That is up +17% on the projected 2030 average. Momentum favours further upside here.
The RNAC price prediction for 2032 points to an average of $15.52 (low $10.31, high $25.29) — a potential gain of +99% on today's $7.80. Buyers look set to stay in control over this stretch.
In 2033, RNAC is projected to trade between $9.97 and $25.59, averaging $15.37 — a potential gain of +97% from today's $7.80. That is -1% versus the projected 2032 average. Momentum favours further upside here.
Cartesian Therapeutics, Inc.'s 2034 outlook centres on $15.80, within a $10.02 to $26.83 range. That is up +3% on the projected 2033 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RNAC could reach as high as $28.67, with a base case around $16.58 and support toward $10.29 — roughly +113% from $7.80. Momentum favours further upside here.
Expect RNAC to range from $15.27 to $50.70 through 2040. The $27.19 average target implies a +249% move from current prices. That is up +64% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RNAC price prediction for 2050 points to an average of $43.54 (low $20.41, high $90.44) — a potential gain of +458% on today's $7.80. Momentum favours further upside here.
Investing $1,000 in RNAC today (≈ 128.205128 RNAC) could be worth
$5,582.53
+$4,582.53 (+458%) by 2050 · US Dollar
Based on the average projected RNAC price of $43.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNACwould be worth at today's price.
$1,000 invested in RNAC on Jul 31, 2025 (≈ 78.06401 RNAC) would be worth
$608.9
-$391.1 (-39.1%) today · 0.61× · US Dollar
Based on a RNAC entry price of $12.81 vs. today's $7.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.88 | $989.85 | -1.0% |
| 1 month ago | $10.18 | $766.21 | -23.4% |
| 3 months ago | $6.22 | $1,254.02 | +25.4% |
| 6 months ago | $6.79 | $1,148.75 | +14.9% |
| 1 year ago | $12.81 | $608.9 | -39.1% |
| All time (5.0y) ago | $111 | $70.27 | -93.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNAC forecast.
Our base-case forecast reaches $16.00 around 2035.
Implied market cap at $16.00: $470.1M
The multi-year forecast shows a bullish tilt beginning in 2030 and extending through 2050 and beyond. The 2030 average price is $10.59 with a forecast ROI of 33.7 and a bullish sentiment, followed by continued upside in 2031 ($12.64 average, ROI 59.6, bullish) and 2032 ($14.95 average, ROI 88.8, bullish). The trajectory remains bullish through 2035, with 2035 average $15.27 and ROI 92.8.
Looking further out, 2040 carries a strong up move to an average of $25.81 with a large projected ROI of 225.9 and bullish sentiment, while 2050 projects an average of $38.10 with a projected ROI of 381 and bullish sentiment. These figures illustrate a long-term upside potential despite a variable near-term pace. The figures are estimates and not guarantees, and real returns depend on future market conditions and clinical outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $10.59 with a min of $7.13 and a max of $17.04, and a forecast ROI of 33.7 with a bullish sentiment.
Forecasts indicate neutral sentiment through 2028 with gradual price growth, shifting to bullish from 2030 onward. The 2030–2050 averages rise to $10.59, $25.81, and $38.10 respectively, with ROIs of 33.7, 225.9, and 381 as the long-term upside potential, though these are estimates, not guarantees.
Yes, the 2040 max price in the forecast is $50.87, with an average of $25.81 and an ROI of 225.9, and a bullish sentiment.
RNAC is currently priced at $7.92, with a market cap of $232.7M and a rank of 3617.
In the near term, the 30-day range is $6.01 to $10.44, with a current price of $7.92. The RSI is 40, the SMA50 is $8.29, the SMA200 is $7.63, and there is support at $7.43 with resistance at $10.59.
Cartesian Therapeutics, Inc. Community Discussion
0Share your Cartesian Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.